Back to Search
Start Over
In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II
- Source :
-
Bioorganic & Medicinal Chemistry Letters . Aug2010, Vol. 20 Issue 15, p4719-4723. 5p. - Publication Year :
- 2010
-
Abstract
- Abstract: Spirocyclopropane- and spiroazetidine-substituted tetracycles 13D–E and 16A are described as orally active MK2 inhibitors. The spiroazetidine derivatives are potent MK2 inhibitors with IC50 <3nM and inhibit the release of TNFα (IC50<0.3μM) from hPBMCs and hsp27 phosphorylation in anisomycin stimulated THP-1 cells. The spirocyclopropane analogues are less potent against MK2 (IC50 =0.05–0.23μM), less potent in cells (IC50 <1.1μM), but show good oral absorption. Compound 13E (100mg/kg po; bid) showed oral activity in rAIA and mCIA, with significant reduction of swelling and histological score. [Copyright &y& Elsevier]
Details
- Language :
- English
- ISSN :
- 0960894X
- Volume :
- 20
- Issue :
- 15
- Database :
- Academic Search Index
- Journal :
- Bioorganic & Medicinal Chemistry Letters
- Publication Type :
- Academic Journal
- Accession number :
- 52305309
- Full Text :
- https://doi.org/10.1016/j.bmcl.2010.04.023